Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of RhuDex granules with placebo in the treatment of primary biliary cholangitis

Trial Profile

Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of RhuDex granules with placebo in the treatment of primary biliary cholangitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AV 1142742 (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RhuDex vs placebo in PBC
  • Sponsors Dr Falk Pharma

Most Recent Events

  • 04 Feb 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
  • 15 Jun 2023 This trial has been completed in Germany (Global end date: 3 May 2023).
  • 03 May 2023 This trial has been discontinued in Poland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top